Strongbridge Biopharma plc (NASDAQ:SBBP) is struggling to gain traction with investors, as evidenced by its 0.22 million shares volume. The daily trading volume average remained 0.14 million shares over the course of 3 months. The stock had opened the regular trading at $6 and managed a 6.72% price change to reach $6.35 through the close.Strongbridge Biopharma plc (SBBP) Analyst Opinion
Strongbridge Biopharma plc has a consensus buy rating from 5 Wall Street analysts, and the number of shares currently sold short amount to at least 2.37% of shares outstanding. The stock spiked 3.25% last month and is up 164.58 this year. Wall Street is only getting more bullish on the stock, with 5 of analysts who cover SBBP having a buy-equivalent rating. Analysts have placed a $13.2 price target on Strongbridge Biopharma plc, suggesting a 107.87% gain from recent close. It’s currently trading about -28.25% below its 52-week high.Strongbridge Biopharma plc Earnings Surprise
Strongbridge Biopharma plc (SBBP) revenue totaled $2.02 million up 32.03% from the previous quarter.Strongbridge Biopharma plc (NASDAQ:SBBP) Intraday View
This stock (SBBP) is ahead of its 52-week low with 217.5%. Its last month’s stock price volatility remained 7.36% which for the week stands at 6.1%. The share price has moved forward from its 20 days moving average, trading at a distance of 7.65% and stays -0.17% away from its 50 days moving average. Over the last five days, shares have managed 10.43% gains and now is up 17.99% since hitting its 200-day moving average of $6.08. Strongbridge Biopharma plc (SBBP) has made its way to a 12-month gain of 53.01%.
Turning to Repligen Corporation (NASDAQ:RGEN), its shares were trading at $34.5 a gain of $1.24, on the trading floor. The stock, after opening at $33.58, touched a high of $34.53 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.5. Repligen Corporation has 3 buy ratings, 1 holds and 0 sells even after the stock tumbled -26.3% from its high of $46.81 to a $1.52 billion market value through last close.Repligen Corporation (RGEN) Consensus Price Target
The company’s consensus rating on Reuter’s scale improved from 1.67 to 1.71 during a month. Analysts set a 12-month price target of $46.8 a share. The target implies a 35.65% spike from where the shares are currently trading. Also, the current price highlights a discount of 44.93% to analysts’ high consensus price target.Repligen Corporation (NASDAQ:RGEN) Intraday Trading
The counter witnessed a trading volume of 0.62 million shares versus an average volume of 0.43 million shares during last trading session. Its last month’s stock price volatility remained 3.23% which for the week approaches 4.24%. The lowest price the stock reached in the last trading day was $32.97 and compares with the $28.48 52-week low. The stock recovered 21.16% since its low point and has performed 11.94% year-to-date.